Advertisement
Advertisement
SGMO
Sangamo Therapeutics, Inc. Common Stock
0.34
USDSponsored
-0.01
-2.42%
Mar 26, 12:48 UTC -4
Open
SGMO Earnings Reports
Positive Surprise Ratio
SGMO beat 21 of 39 last estimates.
54%
Next Report
Next Week
Date of Next Report
Mar 30, 2026
Estimate for Q4 25 (Revenue/ EPS)
$20.71M
/-$0.06
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q4 24 (Revenue/ EPS)
+174.22%
/-45.45%
Sangamo Therapeutics, Inc. Common Stock earnings per share and revenue
On --, SGMO reported earnings of -- USD per share (EPS) for -- --, -- the estimate of -- USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a --% difference.
Looking ahead to Q4 25, 8 analysts forecast an EPS of -0.06 USD, with revenue projected to reach 20.71 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
FAQ
What were Sangamo Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q-- --?
For Q-- --, Sangamo Therapeutics, Inc. Common Stock reported EPS of --, Inline estimates by --, and revenue of --, -- -- expectations.
How did the market react to Sangamo Therapeutics, Inc. Common Stock's Q-- -- earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Sangamo Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 30, 2026.
What are the forecasts for Sangamo Therapeutics, Inc. Common Stock's next earnings report?
Based on 8
analysts, Sangamo Therapeutics, Inc. Common Stock is expected to report EPS of -$0.06 and revenue of $20.71M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement